Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

332.53 +3.35 (+1.02%)
Streaming Delayed Price Updated: 3:43 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,791,981
Open 329.18
Bid (Size) 332.49 (2)
Ask (Size) 332.60 (2)
Prev. Close 329.18
Today's Range 329.01 - 333.94
52wk Range 276.83 - 384.44
Shares Outstanding N/A
Dividend Yield 1.02%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Peering Into Eli Lilly's Recent Short Interest
 
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
 
Via Benzinga

Performance

YTD
-8.89%
-8.89%
1 Month
+1.26%
+1.26%
3 Month
-7.06%
-7.06%
6 Month
+8.99%
+8.99%
1 Year
+14.81%
+14.81%

More News

Read More
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years
Via Benzinga
This Is What Whales Are Betting On Eli Lilly
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
Via Investor's Business Daily
Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Eli Lilly's Alzheimer's Candidate Was Found No Better Than Placebo, Fails To Prevent Illness
Via Benzinga
Eli Lilly, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling
Via Benzinga
Why Eli Lilly Stock Cruised to a 3% Gain on Monday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Via Benzinga
A Comprehensive Study Exploring Antibody Services Market : Key Players Eppendorf, Cellab, Cusabio Technology
Via SBWire
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
Via Investor's Business Daily
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via News Direct
Forget Stocks; 2-Year Treasury Bonds Could Pay You More Than These Major Dividend Players
Via Benzinga
Eli Lilly Is Slashing Insulin Prices by 70%. Here's Why Investors Shouldn't Worry.
Via The Motley Fool
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via Benzinga
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
WW Stock Soars As Telehealth Deal Opens Up Hot Obesity Drug Market
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.